1684TiP Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: The phase II INTerpath-012 study
Year: 2025
Type: article
Source: Annals of Oncology
Authors: P.A. Ascierto, C. Robert, M.S. Carlino, A.I. Daud, J.J. Luke, C. Gebhardt, T. Posadas, L.S. Ojalvo, X. Fang, M. Kalabis, G.V. Long
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Institut Gustave Roussy, The University of Sydney, Melanoma Institute Australia, University of California, San Francisco, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Merck Sharp and Dohme
OpenAlex ID: W4415940630